Modification of the existing maximum residue levels for fosetyl/phosphonic acid in apricots, cherries and plums resulting from the use of potassium phosphonates.
MRL
consumer risk assessment
fosetyl
fungicide
phosphonic acid
potassium phosphonates
stone fruits
Journal
EFSA journal. European Food Safety Authority
ISSN: 1831-4732
Titre abrégé: EFSA J
Pays: United States
ID NLM: 101642076
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
entrez:
26
1
2022
pubmed:
27
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant LAINCO S.A. submitted a request to the competent national authority in Greece to modify the existing maximum residue levels (MRLs), currently expressed as fosetyl in the MRL Regulation, resulting from the use of the active substance potassium phosphonates on apricots, cherries and plums. The data submitted in support of the request were found to be sufficient to derive MRL proposals and address the data gap for residue trials compliant with the Southern EU uses identified in the joint MRL review for cherries and plums, but insufficient for apricots. Adequate analytical methods for enforcement are available to control the residues on the commodities under consideration. Based on the risk assessment results, EFSA concluded that the long-term intake of residues resulting from the uses of potassium phosphonates according to the intended agricultural practices is unlikely to present a risk to consumer health.
Identifiants
pubmed: 35079291
doi: 10.2903/j.efsa.2022.7106
pii: EFS27106
pmc: PMC8771293
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e07106Informations de copyright
© 2022 Wiley‐VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.
Références
EFSA J. 2021 Jun 28;19(6):e06673
pubmed: 34194576
EFSA J. 2018 Feb 08;16(2):e05161
pubmed: 32625802
EFSA J. 2018 Jan 15;16(1):e05147
pubmed: 32625691
EFSA J. 2021 Nov 10;19(11):e06926
pubmed: 34795799
EFSA J. 2018 Jul 03;16(7):e05307
pubmed: 32625954
EFSA J. 2021 Aug 25;19(8):e06782
pubmed: 34466160
EFSA J. 2022 Jan 20;20(1):e07106
pubmed: 35079291